An acute myeloid leukaemia diagnosis is one of the most challenging and life-altering moments a patient or family can face. The news often arrives suddenly, bringing with it a flood of unfamiliar terms, urgent decisions, and emotional uncertainty. It is natural to feel overwhelmed as information comes quickly and questions begin to outpace clear answers.
Understanding AML is the first step towards regaining a sense of control. This guide is designed to help you understand AML in a comprehensive way. It explains what the disease is, why it develops, how it presents, and the tests used to confirm it. It also walks you through current treatment approaches, what to expect during care, and how outcomes are assessed.
Whether you are navigating a new diagnosis or trying to support someone close to you, this guide aims to provide clarity, context, and a sense of direction when it is needed most.
Key TakeawaysA quick snapshot of everything you need to know: - What it is: AML is an aggressive blood cancer that begins in the bone marrow, where abnormal myeloid cells multiply rapidly and crowd out healthy blood cells.
- Who it affects: The most common acute leukaemia in adults, with incidence rising significantly after 60. It affects both men and women.
- Key symptoms: Fatigue, frequent infections, unexplained bruising or bleeding, pale skin, shortness of breath, and bone pain.
- How it differs from CML: AML progresses rapidly and requires immediate treatment. Chronic myeloid leukaemia progresses more slowly and is managed differently.
- Diagnosis: Complete blood count, bone marrow biopsy, cytogenetic testing, and molecular profiling.
- Treatment: Induction chemotherapy, consolidation therapy, targeted therapy for specific mutations, and stem cell transplantation for eligible patients.
- Is it curable? Yes, in a meaningful proportion of cases, particularly younger patients with favourable genetics who achieve complete remission and undergo stem cell transplantation.
|
What is Acute Myeloid Leukaemia?
Acute myeloid leukaemia (AML) is a cancer of the blood and bone marrow. It begins when the DNA of a developing myeloid cell undergoes a mutation, causing the cell to grow uncontrollably and produce large numbers of immature, non-functional blast cells. These abnormal cells accumulate in the bone marrow and may enter the bloodstream, gradually crowding out healthy red blood cells, white blood cells, and platelets.
This disruption affects the body’s normal functioning in several ways. A reduced number of red blood cells can lead to anaemia, causing fatigue and weakness. A shortage of healthy white blood cells weakens the immune system, increasing the risk of infections. Low platelet levels can result in easy bruising and bleeding.
The term “acute” is important because it reflects how quickly AML can progress. The disease often develops over days to weeks, which makes early diagnosis and timely treatment essential.
📌 Did You Know? AML is the most common type of acute leukaemia in adults, accounting for around 80% of adult acute leukaemia cases. It is different from acute lymphoblastic leukaemia (ALL), which is more common in children, and chronic myeloid leukaemia (CML), which typically progresses more slow
Acute Myeloid Leukaemia Causes
Acute myeloid leukaemia develops due to acquired genetic mutations in the bone marrow cells responsible for producing blood cells. These changes build up over time and disrupt normal cell development, leading to the uncontrolled growth of immature cells. In most cases, there is no single identifiable cause, and the disease is considered the result of multiple contributing factors rather than one clear trigger.
The known risk factors can be broadly grouped into two categories:
Genetic and Biological Risk Factors
Certain underlying conditions and biological factors can increase the risk of developing AML. These include:
- Previous chemotherapy or radiation therapy, particularly treatments such as alkylating agents used for other cancers
- Pre-existing bone marrow disorders, such as myelodysplastic syndrome or other myeloproliferative disorders that can progress to AML
- Inherited genetic conditions, including Down syndrome, Fanconi anaemia, and Bloom syndrome
- Advancing age, as the body’s ability to repair DNA becomes less efficient, especially after the age of 60
Environmental and Lifestyle Risk Factors
Certain external exposures and lifestyle factors have been linked to an increased risk of developing AML. These include:
- Long-term exposure to benzene, a chemical found in petroleum products and industrial solvents, particularly in manufacturing and industrial settings
- Tobacco smoking, which is known to significantly increase the risk of AML
- High-dose radiation exposure, such as from previous cancer treatment or occupational exposure
- Prolonged exposure to certain pesticides and herbicides, especially in agricultural environments
Acute Myeloid Leukaemia Symptoms
The symptoms of AML reflect the bone marrow's failing ability to produce healthy blood cells. Because AML progresses rapidly, symptoms often develop and worsen over weeks rather than months.
Here is what to watch for:
Symptom | Underlying Cause | When To Seek Help |
Persistent fatigue and weakness | Anaemia due to reduced red blood cell production | Seek medical advice promptly if symptoms are severe or worsening |
Frequent or recurring infections | Reduced number of functional white blood cells affecting immunity | Seek immediate care if infection is accompanied by fever |
Unexplained bruising or bleeding | Low platelet count affecting normal clotting | Seek medical attention promptly, especially if bleeding is spontaneous or prolonged |
Shortness of breath | Reduced oxygen-carrying capacity due to anaemia | Seek immediate care if severe or associated with chest discomfort |
Bone or joint pain | Accumulation of leukaemic cells within the bone marrow | Seek medical advice if pain is persistent or unexplained |
Petechiae (tiny red or purple spots on the skin) | Platelet deficiency leading to small blood vessel bleeding | Seek medical evaluation promptly, as this can be an early sign of AML |
📌 Important: A combination of persistent fatigue, unexplained bruising, and recurrent infections, especially when these symptoms develop over a short period, should not be ignored. This pattern can indicate an underlying blood disorder such as AML and requires urgent medical evaluation.
Acute Myeloid Leukaemia Diagnosis
Diagnosing acute myeloid leukaemia (AML) involves a series of carefully coordinated tests. These not only confirm the presence of the disease but also identify its specific subtype and genetic profile, which play a critical role in determining treatment and expected outcomes.
The diagnostic process typically includes the following steps:
Step 1: Complete Blood Count (CBC)
A CBC is usually the first investigation. It often shows an abnormally high white blood cell count with a large proportion of immature blast cells. At the same time, red blood cells and platelets are typically reduced. A peripheral blood smear may reveal Auer rods, which are rod-shaped structures within blast cells and are strongly suggestive of AML.
Step 2: Bone Marrow Biopsy and Aspirate
A bone marrow sample is essential to confirm the diagnosis. AML is diagnosed when 20 percent or more of the cells in the bone marrow are abnormal blast cells, as defined by international diagnostic criteria.
Step 3: Cytogenetic Testing
This test examines the chromosomes within leukaemia cells to identify structural changes such as translocations, deletions, or inversions. These findings help classify AML into different risk categories and guide treatment planning.
Step 4: Molecular And Genetic Profiling
Advanced testing is performed to detect specific gene mutations such as FLT3, NPM1, IDH1, IDH2, and CEBPA. These mutations provide important information about prognosis and are increasingly used to guide targeted therapies tailored to the patient’s disease profile.
Unsure About Your AML Diagnosis or Treatment Plan?
Get a second opinion from experienced blood cancer specialists.
Acute Myeloid Leukaemia Stages and Classification
Unlike solid tumours, acute myeloid leukaemia (AML) is not staged using a numerical system. Instead, it is classified based on specific disease characteristics that help guide treatment decisions and predict outcomes.
AML is first categorised using the World Health Organization (WHO) classification, which defines subtypes based on cell origin, morphology, and genetic abnormalities. More importantly for clinical practice, AML is stratified into cytogenetic and molecular risk groups, which play a central role in determining prognosis and treatment approach.
These risk groups are broadly divided into:
Risk Group | Key Features | Approximate Five-Year Survival (Younger Adults) | Treatment Implications |
Favourable | t(8;21), inv(16), NPM1 mutation without FLT3-ITD, biallelic CEBPA mutations | 50 to 70% | Standard chemotherapy is often effective; stem cell transplant may not be required in first remission |
Intermediate | Normal karyotype, FLT3-ITD mutation, trisomy 8 | 30 to 50% | Chemotherapy is the mainstay; stem cell transplant is considered based on treatment response and donor availability |
Adverse | Complex karyotype, monosomy 5 or 7, TP53 mutation | 10 to 25% | Intensive treatment is required; stem cell transplant is usually recommended; clinical trials may be considered |
In relapsed or refractory AML, where the disease no longer responds to standard treatment or returns after remission, the leukaemic cells often become more resistant. Management at this stage focuses on salvage therapies where feasible, along with supportive and palliative care to control symptoms, maintain quality of life, and support the patient with dignity.
Acute Myeloid Leukaemia vs Chronic Myeloid Leukaemia
Both conditions arise from myeloid cells in the bone marrow, but they differ significantly in how they develop, progress, and are treated. Understanding these differences is important for accurate diagnosis and appropriate care.
Feature | Acute Myeloid Leukaemia (AML) | Chronic Myeloid Leukaemia (CML) |
Disease progression | Rapid onset and progression over days to weeks | Slow, gradual progression over months to years |
Cell type involved | Immature blast cells that do not function normally | More mature cells that retain partial function |
Symptoms at presentation | Often severe and sudden, including fatigue, infections, and bleeding | May be mild or absent initially; often detected on routine blood tests |
Urgency of treatment | Requires immediate treatment | Treatment can often be planned in a more controlled manner |
Genetic hallmark | Multiple mutations; no single defining abnormality in most cases | Presence of the Philadelphia chromosome (BCR-ABL fusion gene) |
Treatment approach | Intensive chemotherapy, targeted therapy, and possible stem cell transplant | Targeted oral therapy such as tyrosine kinase inhibitors |
Prognosis | Variable; depends on risk group and response to treatment | Generally favourable with long-term disease control in many patients |
While both are forms of blood cancer, AML is an aggressive condition requiring urgent care, whereas CML often follows a more controlled course with effective long-term treatment options available.
Acute Myeloid Leukaemia Treatment
Treatment for acute myeloid leukaemia (AML) begins as soon as the diagnosis is confirmed, given the rapid progression of the disease. The primary goals are to eliminate leukaemic cells, restore normal blood cell production, and reduce the risk of relapse. The treatment plan is individualised based on factors such as age, overall fitness, cytogenetic risk group, and molecular profile.
Here is a comprehensive overview of the main treatment approaches:
Treatment Type | What It Involves | When It Is Used |
Induction Chemotherapy | Intensive combination chemotherapy aimed at achieving complete remission, commonly using the “7+3” regimen with cytarabine and an anthracycline | First-line treatment for most medically fit AML patients |
Consolidation Chemotherapy | Additional chemotherapy given after remission to eliminate residual leukaemic cells and reduce the risk of relapse | All patients who achieve complete remission following induction therapy |
Targeted Therapy | Use of drugs such as FLT3 inhibitors (midostaurin, gilteritinib) and IDH1 or IDH2 inhibitors (ivosidenib, enasidenib) to act on specific genetic mutations | Patients with confirmed actionable mutations such as FLT3, IDH1, or IDH2 |
Stem Cell Transplantation | High-dose chemotherapy followed by infusion of healthy donor stem cells to restore bone marrow function and provide a graft-versus-leukaemia effect | Typically recommended for intermediate and adverse risk patients in remission, and in relapsed or refractory AML |
Hypomethylating Agents | Lower-intensity treatments such as azacitidine or decitabine that slow disease progression | Older patients or those who are not suitable for intensive chemotherapy |
Supportive Care | Blood transfusions, infection management, growth factors, and nutritional support to manage symptoms and treatment side effects | Provided throughout all phases of treatment to maintain stability and quality of life |
For those seeking comprehensive acute myeloid leukaemia treatment and blood cancer care at a specialised centre, Artemis Hospitals offers the full spectrum of AML management under one roof, from accurate diagnosis and risk stratification to advanced therapies and supportive care tailored to each patient’s needs.
Survival Rate and Prognosis
The prognosis of acute myeloid leukaemia (AML) varies widely based on factors such as age, cytogenetic risk group, and response to treatment. It is important to understand that these figures are based on population-level data. Individual outcomes depend on the specific disease subtype, molecular profile, overall health, and the expertise of the treating medical team.
Patient Group | Approximate Five-Year Survival | Key Influencing Factors |
Younger adults (under 60), favourable risk | 50 to 70% | Favourable cytogenetics, ability to achieve complete remission, suitability for standard therapy |
Younger adults (under 60), intermediate risk | 30 to 50% | Depth of treatment response, molecular profile, and availability of a suitable stem cell donor |
Younger adults (under 60), adverse risk | 10 to 25% | High-risk cytogenetics, presence of mutations such as TP53, and overall treatment response |
Older adults (60 and above) | 5 to 15% | Presence of other medical conditions, tolerance to therapy, and underlying risk category |
Across all groups, certain factors consistently improve outcomes. These include early diagnosis, timely access to a specialised haemato-oncology team, treatment guided by detailed molecular profiling, and access to stem cell transplantation when clinically appropriate.
Take the Next Step Toward Expert AML Care
Book a consultation with a cancer specialist today.
Why Choose Artemis Hospitals For AML Treatment?
An acute myeloid leukaemia (AML) diagnosis requires care that is both clinically advanced and deeply patient-focused. At Artemis Hospitals, Gurgaon, treatment is tailored to each patient’s disease profile, overall health, and personal circumstances, ensuring a balanced approach that combines medical precision with compassionate support.
Here is what sets Artemis Hospitals apart:
Dedicated Cancer Centre
Artemis offers a comprehensive oncology facility where haemato-oncologists, medical oncologists, pathologists, and supportive care teams work together. Each AML case is carefully evaluated from multiple clinical perspectives before finalising a treatment plan.
Expert Haemato-Oncology Team
The team at Artemis brings specialised experience across the full spectrum of AML, including newly diagnosed cases, high-risk disease, and relapsed or refractory AML. Treatment decisions are guided by the latest evidence and molecular profiling-based protocols.
Bone Marrow Transplant Programme
Artemis has a well-established transplant programme with expertise in both matched sibling and unrelated donor transplants. The programme is supported by a dedicated transplant unit with strict infection control measures to ensure patient safety.
Targeted And Precision Therapy
Molecular profiling is an integral part of the diagnostic process at Artemis. This enables the use of targeted therapies such as FLT3 and IDH inhibitors, allowing treatment to be aligned with the patient’s specific genetic profile.
Multidisciplinary Tumour Board
Complex AML cases are reviewed by a multidisciplinary tumour board comprising haematologists, oncologists, transplant specialists, and pathologists. This collaborative approach ensures that every patient receives a well-considered and personalised treatment strategy.
JCI And NABH Accreditation
As the first hospital in Gurgaon to achieve both Joint Commission International (JCI) and NABH accreditation, Artemis Hospitals follows internationally recognised standards of clinical quality and patient safety.
For patients seeking comprehensive AML care in India, Artemis Hospitals offers the expertise, advanced treatment options, and supportive environment needed to manage this condition with confidence and clarity.
Taking the Next Step
An acute myeloid leukaemia diagnosis can feel overwhelming, but the right medical team can make a meaningful difference. Early evaluation and timely treatment by an experienced haemato-oncology team are critical to improving outcomes and guiding patients through each stage of care with clarity and confidence.
Whether you are newly diagnosed, seeking a second opinion, or exploring advanced treatment options for relapsed or refractory AML, the team at Artemis Hospitals is equipped to support you with expertise and compassion.
To book an appointment with a specialist at Artemis Hospitals, call our customer care at +91-124-451-1111 or WhatsApp us at +91 98004 00498. You can also schedule an appointment through our online patient portal or download and register on the Artemis Personal Health Record mobile app, available for both iOS and Android devices.
Article by Dr. Sukriti Gupta
Sr. Consultant - Hematology, Paediatric Haemato-Oncology & BMT
Artemis Hospitals
